- Home
- MOLN vs DOUG Comparison
MOLN vs DOUG Comparison
Compare MOLN & DOUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOLN
- DOUG
- Stock Information
- Founded
- MOLN 2004
- DOUG 1911
- Country
- MOLN Switzerland
- DOUG United States
- Employees
- MOLN N/A
- DOUG N/A
- Industry
- MOLN
- DOUG Building operators
- Sector
- MOLN
- DOUG Real Estate
- Exchange
- MOLN Nasdaq
- DOUG Nasdaq
- Market Cap
- MOLN 183.2M
- DOUG N/A
- IPO Year
- MOLN 2021
- DOUG N/A
- Fundamental
- Price
- MOLN $3.88
- DOUG $1.73
- Analyst Decision
- MOLN
- DOUG
- Analyst Count
- MOLN 0
- DOUG 0
- Target Price
- MOLN N/A
- DOUG N/A
- AVG Volume (30 Days)
- MOLN 4.4K
- DOUG 533.7K
- Earning Date
- MOLN 03-06-2025
- DOUG 03-11-2025
- Dividend Yield
- MOLN N/A
- DOUG N/A
- EPS Growth
- MOLN N/A
- DOUG N/A
- EPS
- MOLN N/A
- DOUG N/A
- Revenue
- MOLN $5,484,562.00
- DOUG $995,627,000.00
- Revenue This Year
- MOLN N/A
- DOUG $17.61
- Revenue Next Year
- MOLN $528.57
- DOUG N/A
- P/E Ratio
- MOLN N/A
- DOUG N/A
- Revenue Growth
- MOLN N/A
- DOUG 4.19
- 52 Week Low
- MOLN $3.32
- DOUG $1.00
- 52 Week High
- MOLN $12.70
- DOUG $2.98
- Technical
- Relative Strength Index (RSI)
- MOLN 39.32
- DOUG 43.72
- Support Level
- MOLN $3.76
- DOUG $1.75
- Resistance Level
- MOLN $4.56
- DOUG $1.95
- Average True Range (ATR)
- MOLN 0.29
- DOUG 0.09
- MACD
- MOLN 0.02
- DOUG -0.01
- Stochastic Oscillator
- MOLN 11.87
- DOUG 15.00
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.